The amyloid and tau platform for dementia as a bio-clinical entity is being further stabilized through detection of genetic biomarkers such as Aβ42 and tau species in cerebro-spinal fluid (e.g. Sonnen et al., 2008). Here, MAPT is linked to dementia.